Abstract
It has become apparent in the last years that metal ion homeostasis and its dysfunction which results in increased accumulation in brain, notably of copper, iron and zinc, may be associated with a number of neurodegenerative diseases, such that chelation therapy may be one therapeutic option. We briefly outline chelators currently available together with strategies to develop new chelators capable of crossing the blood-brain-barrier. The homeostasis of iron in brain together with changes in brain iron with ageing are reviewed as well as the role of iron in Parkinson’s disease, and the potential of chelation therapy in PD. Copper and zinc homeostasis in brain and ageassociated changes are then outlined, along with a discussion of the possible involvement of Zn, Cu and Fe in Alzheimer’s disease. We conclude with a brief summary of chelation therapy in AD.
Keywords: chelation, neurodegeneration, iron, copper, zinc
Current Medicinal Chemistry
Title:Chelating Agents for Neurodegenerative Diseases
Volume: 19 Issue: 17
Author(s): R. J. Ward, D. T. Dexter and R. R. Crichton
Affiliation:
Keywords: chelation, neurodegeneration, iron, copper, zinc
Abstract: It has become apparent in the last years that metal ion homeostasis and its dysfunction which results in increased accumulation in brain, notably of copper, iron and zinc, may be associated with a number of neurodegenerative diseases, such that chelation therapy may be one therapeutic option. We briefly outline chelators currently available together with strategies to develop new chelators capable of crossing the blood-brain-barrier. The homeostasis of iron in brain together with changes in brain iron with ageing are reviewed as well as the role of iron in Parkinson’s disease, and the potential of chelation therapy in PD. Copper and zinc homeostasis in brain and ageassociated changes are then outlined, along with a discussion of the possible involvement of Zn, Cu and Fe in Alzheimer’s disease. We conclude with a brief summary of chelation therapy in AD.
Export Options
About this article
Cite this article as:
J. Ward R., T. Dexter D. and R. Crichton R., Chelating Agents for Neurodegenerative Diseases, Current Medicinal Chemistry 2012; 19 (17) . https://dx.doi.org/10.2174/092986712800609689
DOI https://dx.doi.org/10.2174/092986712800609689 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial: (Thematic Issue) Novel Concepts on the Blood-Brain Barrier and Brain Pathology. New Therapeutic Approaches
CNS & Neurological Disorders - Drug Targets Tactile Angle Discrimination Decreases due to Subjective Cognitive Decline in Alzheimer’s Disease
Current Alzheimer Research Oligomeric Amyloid β -Protein as a Therapeutic Target in Alzheimers Disease: Its Significance Based on its Distinct Localization and the Occurrence of a Familial Variant Form
Current Alzheimer Research Functional Interactions of Tau and their Relevance for Alzheimers Disease
Current Alzheimer Research Clinical Significance of Pleiotropic Effects of Statins: Lipid Reduction and Beyond
Current Medicinal Chemistry Curcuminoids and Novel Opportunities for the Treatment of Alzheimer's Disease: Which Molecules are Actually Effective?
Current Molecular Pharmacology Polypharmacology in a Single Drug: Multitarget Drugs
Current Medicinal Chemistry Alcohol Consumption, Dementia and Cognitive Decline: An Overview of Systematic Reviews
Current Clinical Pharmacology Editorial [Hot Topic: Applications of Angiotensin Converting Enzyme Inhibitors and of Angiotensin II Receptor Blockers in Pharmacology and Therapy: An Update (Executive Editor: Agostino Molteni)]
Current Pharmaceutical Design Commentary: Hot, Hotter, and Hottest Trends in α-Synuclein Research
Current Protein & Peptide Science Amyloid PET and MRI in Alzheimers Disease and Mild Cognitive Impairment
Current Alzheimer Research Tau PET Distributional Pattern in AD Patients with Visuospatial Dysfunction
Current Alzheimer Research Heat Shock Proteins as Suppressors of Accumulation of Toxic Prefibrillar Intermediates and Misfolded Proteins in Neurodegenerative Diseases
Current Pharmaceutical Biotechnology The Emergent Cardiovascular Risk Factors and Organ Damage in Arterial Hypertension
Current Hypertension Reviews Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders
Current Pharmaceutical Design Neurodegenerative Disorders and the Current State, Pathophysiology, and Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Dietary Fat Intake and Risk of Alzheimer’s Disease and Dementia: A Meta-Analysis of Cohort Studies
Current Alzheimer Research Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Current Neuropharmacology Variability in Individual Responsiveness to Aspirin: Clinical Implications and Treatment
Cardiovascular & Hematological Disorders-Drug Targets “The Future Magic Bullet”: A Review of Pharmacological Activities of Ethyl Pyruvate and its Derivatives
Current Drug Therapy